本报记者 马宇薇 当前，胶原蛋白产业迎来需求扩容与赛道升级的双重机遇，应用场景从传统大健康领域向新材料应用、 纺织等多领域延伸，行业也步入全产业链、技术创新的综合比拼阶段。 在这样的市场环境下，有六十余年发展史的胶原企业包头东宝生物技术股份有限公司（以下简称"东宝 生物"），正凭借全产业链优势和"胶原+"战略，探索差异化发展之路：一方面持续加码研发投入，攻关 研发新型胶原产品，精准匹配消费者多元化需求；另一方面积极布局海外市场，主动挖掘发展新空间、 新机遇。 近日，《证券日报》记者走进东宝生物，探寻这家历史悠久的胶原企业的发展战略。 锁定胶原主业持续深耕 东宝生物的发展历程，是国内胶原产业迭代升级的生动注脚。1960年，东河区白明胶厂（东宝生物前 身）作为内蒙古最早涉足明胶产业的企业之一，依托包头当地丰富的原料资源，正式开启与胶原的不解 之缘，为后续发展积累了宝贵经验与技术基础。 历经三十多年的摸索与积淀，1997年，企业顺利完成改制，正式成立包头东宝（集团）明胶有限公司， 并于2000年完成股改，更名为"包头东宝生物技术股份有限公司"，企业自此迈入规范化、市场化发展阶 段。改制后，东宝生物明确以明胶为主业方 ...

证券代码：300239 证券简称：东宝生物 公告编号：2026-003 债券代码：123214 债券简称：东宝转债 包头东宝生物技术股份有限公司 关于 2022 年员工持股计划存续期即将届满的提示性公告 4、2025年4月22日，公司召开第九届董事会第十次会议审议通过了《关于修 订2022年员工持股计划(草案)及摘要、管理办法并对存续期展期的议案》，同意 对本员工持股计划存续期展期12个月，即存续期展期至2026年7月28日。 上述具体内容详见公司在创业板信息披露网站巨潮资讯网披露的相关公告。 截至本公告披露日，本员工持股计划已全部解锁，持有公司股票16,248,404 股，占公司目前总股本的2.74%。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 包头东宝生物技术股份有限公司(以下简称"公司")于2022年6月30日召开 了第八届董事会第五次会议、第八届监事会第五次会议(全体监事为关联监事， 直接提交股东大会表决)，2022年7月18日召开2022年第一次临时股东大会，审议 通过了《关于<包头东宝生物技术股份有限公司2022年员工持股计划(草案)>及其 ...

Group 1 - The biopharmaceutical sector increased by 0.19% on January 21, with Nearshore Protein leading the gains [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] - Key stocks in the biopharmaceutical sector showed significant price increases, with Nearshore Protein rising by 6.37% to a closing price of 48.76 [1] Group 2 - The biopharmaceutical sector experienced a net inflow of 77.04 million yuan from institutional investors, while retail investors saw a net outflow of 284 million yuan [2] - Major stocks like Watson Bio and Ganli Pharmaceutical attracted significant institutional investment, with net inflows of 64.45 million yuan and 55.25 million yuan, respectively [3] - Retail investors showed a negative trend in several stocks, with Watson Bio and Ganli Pharmaceutical experiencing net outflows of 33.30 million yuan and 39.14 million yuan, respectively [3]

1月21日，东宝生物涨5.06%，截至发稿，报6.44元/股，成交1.42亿元，换手率3.83%，总市值38.23亿 元。 资料显示，包头东宝生物技术股份有限公司位于内蒙古自治区包头市稀土高新技术产业开发区黄河大街 46号，成立日期1997年3月12日，上市日期2011年7月6日，公司主营业务涉及明胶系列产品及小分子量 胶原蛋白的研发、生产、销售。主营业务收入构成为：胶囊业务54.13%，明胶系列产品及副产品磷酸 氢钙37.30%，胶原蛋白业务7.81%，有机肥业务0.53%，其他(补充)0.22%。 广发聚丰混合A（270005）成立日期2005年12月23日，最新规模33.66亿。今年以来收益11.92%，同类 排名540/8844；近一年收益70.13%，同类排名640/8091；成立以来收益556.36%。 广发聚丰混合A（270005）基金经理为苏文杰。 截至发稿，苏文杰累计任职时间7年93天，现任基金资产总规模97.34亿元，任职期间最佳基金回报 167.69%， 任职期间最差基金回报5.18%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股 ...

Market Overview - The biopharmaceutical sector experienced a decline of 1.05% on January 16, with Olin Bio leading the drop [1] - The Shanghai Composite Index closed at 4101.91, down 0.26%, while the Shenzhen Component Index closed at 14281.08, down 0.18% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Wanzhe Co., Ltd. (000534) with a closing price of 22.85, up 3.02% and a trading volume of 251,300 shares, totaling 589 million yuan [1] - Wendi Pharmaceutical (688488) closed at 21.60, up 2.96% with a trading volume of 289,600 shares, totaling 597 million yuan [1] - Sanofi Biopharmaceuticals (688336) closed at 58.88, up 2.56% with a trading volume of 47,400 shares, totaling 279 million yuan [1] - Major decliners included: - Olin Bio (6158888) closed at 24.75, down 15.21% with a trading volume of 189,400 shares, totaling 515 million yuan [2] - Kanglao Health (920575) closed at 9.81, down 5.40% with a trading volume of 139,800 shares, totaling 139 million yuan [2] - Dongbao Bio (300239) closed at 6.19, down 3.88% with a trading volume of 214,700 shares, totaling 135 million yuan [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 681 million yuan from institutional investors, while retail investors contributed a net inflow of 337 million yuan [2] - The capital flow for specific stocks showed: - Aidi Pharmaceutical (688488) had a net inflow of 37.04 million yuan from institutional investors, but a net outflow of 44.62 million yuan from retail investors [3] - Wanzhe Co., Ltd. (000534) had a net inflow of 29.97 million yuan from institutional investors, with a net outflow of 39.12 million yuan from retail investors [3] - Te Bao Bio (688278) had a net inflow of 4.89 million yuan from institutional investors, but a net outflow of 5.01 million yuan from retail investors [3]

Market Overview - The biopharmaceutical sector experienced a slight decline of 0.06% on January 12, with Sanofi leading the drop [1] - The Shanghai Composite Index closed at 4165.29, up 1.09%, while the Shenzhen Component Index closed at 14366.91, up 1.75% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Dongbao Biological (300239) with a closing price of 6.60, up 10.92% and a trading volume of 575,100 shares, totaling 366 million yuan [1] - Changchun High-tech (000661) closed at 103.57, up 5.79%, with a trading volume of 169,400 shares, totaling 1.725 billion yuan [1] - ST Weiming (002581) closed at 7.83, up 4.96%, with a trading volume of 71,500 shares, totaling 54.3049 million yuan [1] - Conversely, significant decliners included: - Sanofi (688336) closed at 59.81, down 6.25%, with a trading volume of 93,200 shares, totaling 560 million yuan [2] - Teva Biopharma (688278) closed at 76.96, down 4.50%, with a trading volume of 41,600 shares, totaling 323 million yuan [2] - Aidi Pharmaceutical (688488) closed at 16.90, down 4.41%, with a trading volume of 98,600 shares, totaling 168 million yuan [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 240 million yuan from institutional investors, while retail investors contributed a net inflow of 272 million yuan [2] - Key stocks with significant capital flow included: - Changchun High-tech (000661) had a net inflow of 122 million yuan from institutional investors, while retail investors saw a net outflow of 77.57 million yuan [3] - Dongbao Biological (300239) experienced a net inflow of 22.51 million yuan from institutional investors, with retail investors also seeing a net outflow of 10.81 million yuan [3] - Sanofi (688336) had a net inflow of 21.21 million yuan from institutional investors, while retail investors had a net inflow of 28.87 million yuan [3]

Market Performance - The biopharmaceutical sector increased by 0.55% on January 6, with Liaoning Chengda leading the gains [1] - The Shanghai Composite Index closed at 4083.67, up by 1.5%, while the Shenzhen Component Index closed at 14022.55, up by 1.4% [1] Individual Stock Performance - Liaoning Chengda (600739) closed at 12.27, with a rise of 7.16% and a trading volume of 530,500 shares, amounting to a transaction value of 633 million yuan [1] - Dongbao Biological (300239) closed at 6.18, up by 5.64%, with a trading volume of 454,500 shares and a transaction value of 278 million yuan [1] - Olin Biological (616889) closed at 27.66, increasing by 3.83%, with a trading volume of 74,400 shares and a transaction value of 204 million yuan [1] - Kanghong Pharmaceutical (002773) closed at 33.75, up by 2.37%, with a trading volume of 249,700 shares and a transaction value of 838 million yuan [1] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 426 million yuan from institutional investors, while retail investors saw a net inflow of 323 million yuan [2] - The net inflow from speculative funds was 104 million yuan [2] Detailed Capital Flow for Selected Stocks - Liaoning Chengda had a net inflow of 34.37 million yuan from institutional investors, while it faced a net outflow of 18.32 million yuan from retail investors [3] - Dongbao Biological saw a net inflow of 21.29 million yuan from institutional investors, with a net outflow of 13.16 million yuan from retail investors [3] - Tian Tan Biological (600161) had a net inflow of 18.06 million yuan from institutional investors, with a net outflow of 10.02 million yuan from retail investors [3]

Group 1 - The core point of the article highlights the recent performance of Dongbao Bio, with a stock price increase of 5.13% to 6.15 CNY per share, a trading volume of 97.52 million CNY, a turnover rate of 2.77%, and a total market capitalization of 3.651 billion CNY [1] - Dongbao Bio, established on March 12, 1997, and listed on July 6, 2011, is located in Baotou, Inner Mongolia, and specializes in the research, production, and sales of gelatin products and low molecular weight collagen [1] - The main business revenue composition of Dongbao Bio includes capsule business at 54.13%, gelatin series products and by-products at 37.30%, collagen business at 7.81%, organic fertilizer business at 0.53%, and other supplementary products at 0.22% [1] Group 2 - From the perspective of the top ten circulating shareholders, Guangfa Fund has a fund that ranks among Dongbao Bio's top ten circulating shareholders, specifically Guangfa Jufeng Mixed A (270005), which entered the top ten in the third quarter with 4.5228 million shares, accounting for 0.77% of circulating shares [2] - Guangfa Jufeng Mixed A (270005) was established on December 23, 2005, with a latest scale of 3.366 billion CNY, and has achieved a year-to-date return of 1.2%, ranking 5853 out of 8816 in its category, and a one-year return of 59.59%, ranking 1201 out of 8081 [2]

包头东宝生物技术股份有限公司 关于 2025 年第四季度可转换公司债券转股情况的公告 | 证券代码：300239 | 证券简称：东宝生物 | 公告编号：2026-002 | | --- | --- | --- | | 债券代码：123214 | 债券简称：东宝转债 | | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、"东宝转债"(债券代码：123214)的转股期限为2024年2月5日至2029年7月30日； 最新有效的转股价格为6.63元/股。 2、2025年第四季度，"东宝转债"未发生转股情况。 3、截至 2025 年第四季度末，公司剩余可转债为 4,549,670 张，剩余票面总金额为 454,967,000 元人民币。 根据《深圳证券交易所创业板股票上市规则》和《深圳证券交易所上市公司自律监 管指引第15号——可转换公司债券》的有关规定，包头东宝生物技术股份有限公司(以 下简称"公司"或"东宝生物")现将2025年第四季度可转换公司债券转股及公司总股本变 化情况公告如下： 一、可转换公司债券发行及上市情况 (一)可转债发行情况 经中国 ...

| 证券代码:300239 | | --- | | 债券代码:123214 | 关于回购股份进展暨回购实施结果公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 包头东宝生物技术股份有限公司(以下简称"东宝生物"或"公司")于2025 年1月3日召开第九届董事会第八次会议、第九届监事会第七次会议，审议通过了 《关于回购公司股份方案的议案》，使用公司自有资金和/或自筹资金以集中竞 价交易方式或法律法规允许的方式回购公司已发行的人民币普通股(A股)股票， 回购的公司股份用于实施员工持股计划或股权激励。本次回购股份不低于人民币 5,000万元(含)，且不超过人民币10,000万元(含)，具体回购资金总额以回购期限 届满时或者回购股份实施完毕时实际回购股份使用的成交资金总额为准。本次回 购价格不超过人民币8.00元/股(含)，本次回购股份的实施期限自公司董事会审议 通过回购股份方案之日起12个月内。因公司实施2024年度权益分派，公司本次回 购价格上限由不超过人民币8.00元/股(含)调整为不超过人民币7.98元/股(含)。具 体内容详见公司在巨潮资讯网(www.c ...